MannKind Corp. (MNKD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.06+2.53%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MNKD
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on growing commercial products like Afrezza and Furoscix, advancing clinical programs including MNKD-201 and MNKD-1501, and broadening development pipeline.
Stated as a priority in 3 of last 3 quarters. Revenue grew from $90.2M in 2026-Q1 to $109.4M in 2026-Q2 (+43% vs prior year Q2), driven by Furoscix addition and Afrezza pediatric launch. CEO emphasized FDA approvals and positive clinical data validating diversification strategy, indicating delivering progress.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“CEO: 'Delivered all three major catalysts in 2026 including FDA approvals and positive Phase 1b data, validating diversification strategy.'”
“CEO: 'Making meaningful progress executing corporate transformation strategy focused on expansion and diversification of commercial portfolio and pipeline.'”
“MannKind closed 2025 with strong momentum across commercial portfolio and meaningful progress in pipeline.”
Target full-year 2026 revenue of $349 million, driven by commercial portfolio growth and pipeline progress.
Stated as a priority in 2 of last 3 quarters. Management set 2026 revenue guidance at $349 million. Actual revenue was $90.2M in Q1 and $109.4M in Q2 2026, totaling approximately $199.5M for half year, showing progress toward full-year guidance but trajectory requires continued growth to meet target.
“MannKind closed 2025 with strong momentum across commercial portfolio and meaningful progress in pipeline.”
“2026 revenue guidance of $349 million set by management.”
Progress clinical trials including MNKD-201 Phase 2, MNKD-1501 IND filing, and pediatric Afrezza studies with milestone achievements.
Stated as a priority in 2 of last 3 quarters. Clinical milestones include positive Phase 1b data for MNKD-201 and ongoing Phase 2 enrollment, plus planned IND filing for MNKD-1501. Management's statements align with progress but no revenue impact yet; trajectory shows delivering clinical advancement.
“Positive Phase 1b INFLO-1 data for MNKD-201; Phase 2 INFLO-2 enrollment underway.”
“On track for IND filing of MNKD-1501 by year end; pediatric Afrezza study completed pilot phase.”
Raise capital through private placement to fund corporate needs including $45 million CVR payment related to Furoscix ReadyFlow approval.
Newly stated in 2026-Q2. Company completed a $50 million private placement in July 2026 to fund a $45 million contingent value rights payment triggered by FDA approval of Furoscix ReadyFlow. This capital raise reflects active management of capital allocation to support corporate obligations.
“Entered into $50 million private placement to fund $45 million CVR payment for Furoscix ReadyFlow approval.”
Focus on expanding commercial capabilities through strategic acquisitions like scPharmaceuticals.
Over the trailing year it converted 1.94x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 55% of the time over the next year (vs 45% for the rest of the cohort, n=2490).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
9 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.